Pfizer seeking Schick buyer
This article was originally published in The Rose Sheet
Executive Summary
Pfizer announces it is "exploring strategic options," including possible sale, for its Schick-Wilkinson Sword shaving products and Adams confectionery businesses. With 2001 sales of approximately $620 mil., Schick's top brands include Xtreme III razors and blades, Silk Effects, Protector and FX Diamonds. Both the Schick and Adams businesses became part of Pfizer in June 2000 with the company's merger with Warner-Lambert. Morgan Stanley will act as investment banker for Schick...
You may also be interested in...
BIC won’t get Schick
BIC out of running for Pfizer's Schick-Wilkinson shaving business due to possible regulatory hurdles, BIC announces Sept. 3. BIC contacted Pfizer after shaving business was put up for sale, but the pharmaceutical giant said it would not pursue a deal with BIC because it would take longer to obtain regulatory approval than if it proceeded with other potential buyers, BIC says. BIC will move forward with plans to enter triple-blade razor category with scheduled launch of BIC Comfort 3 Shaver in first quarter 2003, firm adds. Pfizer announced its desire to divest Schick in June (1"The Rose Sheet" July 1, 2002, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.